In-Depth Analysis On Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2017
Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape.
Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.
Complete report available @ Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Crohn’s Disease (Regional Enteritis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Crohn’s Disease (Regional Enteritis) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 11, 28, 25, 37, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn’s Disease (Regional Enteritis) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Crohn’s Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crohn’s Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crohn’s Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crohn’s Disease (Regional Enteritis) (Gastrointestinal)
- The pipeline guide reviews pipeline therapeutics for Crohn’s Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crohn’s Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crohn’s Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crohn’s Disease (Regional Enteritis) (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crohn’s Disease (Regional Enteritis) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crohn’s Disease (Regional Enteritis) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4D Pharma PLC AB Science SA AbbVie Inc Adello Biologics LLC Aerpio Therapeutics Inc Alfa Wassermann SpA Allergan Plc Alteogen Inc Amgen Inc ARA Healthcare Pvt Ltd Arena Pharmaceuticals Inc Astellas Pharma Inc Atlantic Bio Sci LLC BioLingus AG BioTherapeutics Inc Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Calypso Biotech SA Celgene Corp Cellceutix Corp ChemoCentryx Inc ChironWells GmbH CLL Pharma SA Coherus BioSciences Inc Commence Bio Inc Concenter BioPharma Silkim Ltd Daiichi Sankyo Company Ltd DBV Technologies SA Eisai Co Ltd Eli Lilly and Company Enterome Bioscience SA Enzo Biochem Inc Ferring International Center SA Galapagos NV Genentech Inc Genor BioPharma Co Ltd iCo Therapeutics Inc. Iltoo Pharma Immune Response BioPharma Inc Immune Therapeutics Inc Inception Sciences Inc Innovent Biologics Inc Johnson & Johnson Jyant Technologies Inc Kang Stem Biotech Co Ltd KPI Therapeutics Inc Kyorin Pharmaceutical Co Ltd Merck & Co Inc Merck KGaA Mesoblast Ltd Mitsubishi Tanabe Pharma Corp Momenta Pharmaceuticals Inc Mycenax Biotech Inc NeuClone Pty Ltd Novartis AG Oncodesign SA Panacea Biotec Ltd Pfenex Inc Protagonist Therapeutics Inc Protalix BioTherapeutics Inc Qu Biologics Inc Re-Pharm Ltd RedHill Biopharma Ltd Reliance Life Sciences Pvt Ltd Sandoz International GmbH SATT North SAS Second Genome Inc Shire Plc Sigmoid Pharma Ltd Soligenix Inc Stelic Institute & Co Inc Sylentis SAU Synedgen Inc Synlogic Inc TaiwanJ Pharmaceuticals Co Ltd Takeda Pharmaceutical Company Ltd Tiziana Life Sciences Plc Trino Therapeutics Ltd Ventria Bioscience Virobay Inc Vivelix Pharmaceuticals Ltd Xbrane Biopharma AB
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 02:21
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home